RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence

Bibliography

• Goodin DS, Frohman EM, Garmany GP, Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-78
   PubMed Web of Science ®Google Scholar
• Uitdehaag B, Constantinescu C, Cornelisse P, Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord 2011;4:3-14
   PubMedGoogle Scholar
• Goodin DS, Reder AT, Ebers GC, Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN beta-1b trial. Neurology 2012;78:1315-22
   PubMed Web of Science ®Google Scholar
• Miller AE, Rhoades RW. Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs. Curr Opin Neurol 2012;25(Suppl):S4-S10
   PubMedGoogle Scholar
• Comi G. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin Ther 2009;31:1142-57
   PubMed Web of Science ®Google Scholar
• Tintoré M. Early MS treatment. Int MS J 2007;14:5-10
   PubMedGoogle Scholar
• Kappos L, Freedman MS, Polman CH, Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-97
   PubMed Web of Science ®Google Scholar
• Ebers GC, Traboulsee A, Li D, Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010;81:907-12
   PubMed Web of Science ®Google Scholar
• Goodin DS, Traboulsee A, Knappertz V, Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:282-7
   PubMed Web of Science ®Google Scholar
• Brandes DW. The role of glatiramer acetate in the early treatment of multiple sclerosis. Neuropsychiatr Dis Treat 2010;6:329-36
   PubMed Web of Science ®Google Scholar
• Trojano M, Pellegrini F, Paolicelli D, Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol 2009;66:513-20
   PubMed Web of Science ®Google Scholar
• Al-Sabbagh A, Bennet R, Kozma C, Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database. J Neurol 2008;255(Suppl 2):S79
   Google Scholar
• Steinberg SC, Faris RJ, Chang CF, Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010;30:89-100
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O'Connor P, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Portaccio E. Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. Core Evid 2011;6:13-21
   PubMedGoogle Scholar
• Portaccio E, Zipoli V, Siracusa G, Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008;59:131-5
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Schweikert B, Ecari U, Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis–results of the BetaPlus observational cohort study. J Neurol Sci 2011;307:120-6
   PubMed Web of Science ®Google Scholar
• Treadaway K, Cutter G, Salter A, Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256:568-76
   PubMed Web of Science ®Google Scholar
• Wong J, Gomes T, Mamdani M, Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. Can J Neurol Sci 2011;38:429-33
   PubMed Web of Science ®Google Scholar
• Fernandez O, Aguera J, Izquierdo G, Adherence to interferon beta-1b treatment in patients with multiple sclerosis in Spain. PLoS One 2012;7:e35600
   PubMedGoogle Scholar
• Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler 2012;18:932-46
   PubMed Web of Science ®Google Scholar
• Devonshire V, Lapierre Y, Macdonell R, The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:69-77
   PubMed Web of Science ®Google Scholar
• Meyniel C, Spelman T, Jokubaitis VG, Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. PLoS One 2012;7:e38661
   PubMedGoogle Scholar
• O'Connor P, Wolinsky JS, Confavreux C, Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
   PubMed Web of Science ®Google Scholar
• Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003;61:551-4
   PubMed Web of Science ®Google Scholar
• Beer K, Muller M, Hew-Winzeler AM, The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study. BMC Neurol 2011;11:144
   PubMed Web of Science ®Google Scholar
• O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50
   PubMed Web of Science ®Google Scholar
• Mohr DC, Boudewyn AC, Likosky W, Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001;23:125-32
   PubMed Web of Science ®Google Scholar
• Verdun di Cantogno E, Russell S, Snow T. Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices. Patient Prefer Adherence 2011;5:173-80
   PubMed Web of Science ®Google Scholar
• Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opin Drug Deliv 2009;6:995-1002
   PubMed Web of Science ®Google Scholar
• Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence 2010;4:1-9
   PubMed Web of Science ®Google Scholar
• Bayas A, Japp G, Fulda U, Injection devices in the basic therapy of multiple sclerosis. Survey among neurologists, MS nurses and patients [in German]. Nervenheilkunde 2010;29:57-62
   Google Scholar
• Brochet B, Lemaire G, Beddiaf A. Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices. Rev Neurol (Paris) 2006;162:735-40
   PubMed Web of Science ®Google Scholar
• Cramer JA, Cuffel BJ, Divan V, Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand 2006;113:156-62
   PubMed Web of Science ®Google Scholar
• Mikol D, Lopez-Bresnahan M, Taraskiewicz S, A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler 2005;11:585-91
   PubMed Web of Science ®Google Scholar
• de Sá J, Urbano G, Reis L. Assessment of new application system in Portuguese patients with relapsing-remitting multiple sclerosis. Curr Med Res Opin 2010;26:2237-42
   PubMed Web of Science ®Google Scholar
• Exell S, Verdun E, Driebergen R. A new electronic device for subcutaneous injection of IFN beta-1a. Expert Rev Med Devices 2011;85:543-53
   Google Scholar
• Devonshire VA, Verdun di Cantogno E. Review of subcutaneous interferon beta-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis. Ther Deliv 2011;2:1455-65
   PubMedGoogle Scholar
• Thompson I. New-generation auto-injectors – taking self-injection beyond prefilled syringes. Available from: www.touchbriefings.com/pdf/1859/Ypsomed_tech2.pdf [Last accessed 3 August 2012]
   Google Scholar
• RebiSmart™. Geneva, Switzerland: Merck Serono S.A., 2012. Available from: www.rebismart.com/en/index.html [Last accessed 24 August 2012]
   Google Scholar
• Rebiject II®. Rockland, Massachusetts, USA: EMD Serono, 2012. Available from: www.rebif.com/pages/starting-rebif/rebiject_ii [Last accessed 24 August 2012]
   Google Scholar
• RebiDose™. Geneva, Switzerland: Merck Serono S.A., 2010. Available from: www.merckserono.com/en/products/neurodegenerative_diseases/multiple_sclerosis/rebif/rebidose.html [Last accessed 24 August 2012]
   Google Scholar
• Injecting interferon beta-1b with the Betaject® Lite. Berlin, Germany: Bayer Healthcare, 2007. Available from: www.ms-gateway.com/interferon-beta-1b-user-guide/injecting-interferon-beta-1b-with-the-betajectreg-lite-160.htm [Last accessed 24 August 2012]
   Google Scholar
• Injecting interferon beta-1b with the Betaject® Comfort. Berlin, Germany: Bayer Healthcare, 2007. Available from: www.ms-gateway.com/interferon-beta-1b-user-guide/injecting-interferon-beta-1b-with-the-betajectreg-comfort-159.htm [Last accessed 24 August 2012]
   Google Scholar
• Personal Injector™. Copenhagen, Denmark: Union Medico, 2001. Available from: www.personalinjector.com/uk/11.php [Last accessed 24 August 2012]
   Google Scholar
• Avonex® pen. Cambridge, Massachusetts, USA: Biogen Idec, 2012. Available from: www.avonex.com/avonex-pen-injection.xml [Last accessed 24 August 2012]
   Google Scholar
• Autoject® 2. Marietta, Georgia, USA: Owen Mumford, 2012. Available from: www.owenmumford.com/us/range/35/autoject-2.html [Last accessed 24 August 2012]
   Google Scholar
• Extaviject II. East Hanover, New Jersey, USA: Novartis, 2010. Available from: quo.novartis.com/productinfosite/infosites/content/extavia/resources/EXDStarterInjectionTrainingManual.pdf [Last accessed 23 July 2012]
   Google Scholar
• Jaber A, Bozzato GB, Vedrine L, A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis. BMC Neurol 2008;8:38
   PubMed Web of Science ®Google Scholar
• Dahlgren J. Easypod: a new electronic injection device for growth hormone. Expert Rev Med Devices 2008;5:297-304
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Barbarash O, Casset-Semanaz F, Safety and immunogenicity of a new formulation of interferon ß-1a (Rebif® New Formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler 2009;15:219-28
   PubMed Web of Science ®Google Scholar
• McKeage K, Wagstaff AJ. Subcutaneous interferon-beta-1a : new formulation. CNS Drugs 2007;21:871-6
   PubMed Web of Science ®Google Scholar
• Devonshire V, Arbizu T, Borre B, Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. BMC Neurol 2010;10:28
   PubMed Web of Science ®Google Scholar
• Singer B, Wray S, Miller T, Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis. Mult Scler Relat Disord 2012;1:87-94
   PubMed Web of Science ®Google Scholar
• D'Arcy C, Thomas D, Stoneman D, Patient assessment of an electronic device for subcutaneous self-injection of interferon beta-1a for multiple sclerosis: an observational study in the UK and Ireland. Patient Prefer Adherence 2012;6:55-61
   PubMed Web of Science ®Google Scholar
• Lugaresi A, Florio C, Brescia-Morra V, Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurol 2012;12:7
   PubMed Web of Science ®Google Scholar
• NCT01108887: An observational study for the assessment of adherence, effectiveness and convenience of Rebif® treatment in relapsing multiple sclerosis patients using RebiSmart™. Bethesda, Maryland, USA: National Institutes of Health, 2012. Available from: clinicaltrials.gov/archive/NCT01108887 [Last accessed 29 October 2012]
   Google Scholar
• Devonshire V, Feinstein A, Enciu C. MEASURE: a multi-centre, single-arm, observational, 96 week, Phase IV study to evaluate treatment adherence when using RebiSmart™ for self-injection of subcutaneous interferon-beta 1a in multi-dose cartridges in subjects with relapsing multiple sclerosis. J Neurol 2011;258(Suppl 1):S265-6
   Google Scholar
• Clinical trials of RebiSmart™. Bethesda, Maryland, USA: National Institutes of Health, 2012. Available from: clinicaltrials.gov/ct2/results?term=rebismart [Last accessed 24 August 2012]
   Google Scholar
• READOUTsmart: REal ADherence mOnitoring in mUlTiple sclerosis applying the electronic device RebiSmart™. Berlin, Germany: Die forschenden Pharma-Unternehmen, 2011. Available from: www.vfa.de/de/arzneimittel-forschung/datenbanken-zu-arzneimitteln/nisdb/nis-details/_633 [Last accessed 29 October 2012]
   Google Scholar
• Devonshire V, Feinstein A, Fortin K. Anxiety and adherence in patients with relapsing multiple sclerosis using RebiSmart for self-injection: preliminary results from the MEASURE study. J Neurol 2012;259(Suppl 1):S111
   PubMed Web of Science ®Google Scholar
• Devonshire V, Feinstein A, Gillett A. Patients with cognitive impairment maintain good treatment adherence with RebiSmart. Int J MS Care 2012;14(Suppl 2):75
   Google Scholar